Projects / Programmes source: ARIS

New approaches in the treatment of lung cancer II.

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B520  Biomedical sciences  General pathology, pathological anatomy 
B200  Biomedical sciences  Cytology, oncology, cancerology 
lung cancer, mesothelioma, chemotherapy, radiotherapy, combined modality treatment
Evaluation (rules)
source: COBISS
Researchers (9)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  10330  PhD Nikola Bešić  Oncology  Researcher  2008 - 2011  474 
2.  20658  PhD Cvetka Bilban-Jakopin  Medical sciences  Researcher  2008 - 2011  62 
3.  16229  PhD Viljem Kovač  Medical sciences  Researcher  2008 - 2011  297 
4.  20176  PhD Uroš Smrdel  Oncology  Researcher  2008 - 2011  121 
5.  12024  PhD Karmen Stanič  Medical sciences  Researcher  2008 - 2011  94 
6.  27754  PhD Barbara Šegedin  Oncology  Researcher  2008 - 2011  209 
7.  21746  PhD Martina Vrankar  Medical sciences  Researcher  2008 - 2011  132 
8.  11747  PhD Branko Zakotnik  Oncology  Researcher  2008 - 2011  425 
9.  07750  PhD Matjaž Zwitter  Oncology  Head  2008 - 2011  386 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,816 
The project deals with possibilities for improvement of treatment of advanced lung cancer and mesothelioma. According to our hypothesis, modifications of chemotherapy and of irradiation may lead to improved therapeutic ratio between treatment efficacy and its side effects. Our main focus is treatment with low-dose gemcitabine in long infusion. We will continue with 4 clinical trials and bring them to publication, and launch 3 new clinical trials. All togetrher, these studies should recruit a total of 800 patients.
Significance for science
Treatment of advanced cancers (lung, mesothelioma) with low-dose gemcitabine in long infusion opens new perspectives and stimulated basic research, in particular regarding pharmacokinetics of gemcitabine in long infusion. This direction of research is of particular importance since the treatment is of low commercial interest and is therefore to a large extent neglected. This contributes to the originality of our research. Intermittent treatment with chemotherapy and with targeted drugs is a new concept, based on cell kinetics. Our experience with a significant proportion of patients in complete remission is extremely interesting. The concept of intermittent therapy might be applied also to other cancers where chemotherapy and targeted drugs are used (breast, prostate,, kidney..)
Significance for the country
Original clinical trials and publications arising form our clinical research have been received with keen interest among international scientific and medical community. Several research groups folow our experience, in particular those from countries with limited resources (Egypt, India, China) where low-cost treatment contributes to the availability of anti-cancer treatment. This adds to the visibility of our research group and of Slovenian science in the international scientific community.
Most important scientific results Annual report 2008, 2009, final report, complete report on dLib.si
Most important socioeconomically and culturally relevant results Annual report 2008, 2009, final report, complete report on dLib.si
Views history